Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
This special issue of Progress in Neurobiology entitled “Biomarkers for Neurodegenerative Disorders” is a biomarker tour de force as a result of the heroic efforts of the experts in research on chemical and neuroimaging biomarkers of neurodegenerative disorders and related diseases who have contributed superb overviews for this very timely volume. The conditions covered in this special issue range from aging related neurodegenerative diseases that now are epidemic such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), the most common neurodegenerative dementia and movement disorder, respectively, to less common conditions like frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS) and vascular dementia (VaD). Notably, the incidence and prevalence of these disorders are on the rise due to worldwide demographic trends that are leading to rapidly aging populations across the globe (Khachaturian et al., 2009; The Alzheimer’s Study Group Report, 2008; Trojanowski et al., 2010a,b; Plassman et al., 2007; Hurd et al., 2007; Wimo and Prince, 2010). Moreover, it is becoming increasingly clear that the hallmark lesions of PD, such as alpha-synuclein inclusions known as Lewy bodies, and those shared by ALS and FTLD such as TDP-43 pathology, co-occur in AD thereby rendering insights into biomarkers of PD, ALS and FTLD equally relevant to developing informative biomarkers for the onset and progression of AD (see Table 1). Further, the clinical and pathological overlap of AD with PD, ALS and FTLD make it attractive to be able to monitor biomarker evidence for the presence of AD pathology in the brains of patients with these other disorders. In addition, this special issue also includes chapters on biomarkers for schizophrenia, affective disorders and multiple sclerosis because the editors of this special issue and the authors of the chapters here envision many opportunities for advances in biomarker research in each of these areas of neuropsychiatric disease research to cross fertilize and stimulate progress in other areas of biomarker research including research on neurodegenerative disease biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932 · cited 10×
“As noted above, AD is the most common dementia (Khachaturian et al., 2009; The Alzheimer’s Study Group Report, 2008; Trojanowski et al., 2010a,b; Plassman et al., 2007; Hurd et al., 2007; Wimo and Prince, 2010; Hebert et al., 2001; Schneider et al., 2007; White et al., 2005), and the hallmark…”
BackgroundInfluentialRevising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 2×
“…that diagnostic criteria for early AD should be redefined by the presence of memory impairments plus biomarker evidence of AD pathology, although the diagnosis of definite AD still requires an autopsy with postmortem examination of the brain to identify AD neuropathology (Dubois et al., 2010).”
BackgroundSelf-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“Indeed, biomarkers may make it possible to diagnose definitive AD prior to death so that biomarkers can replace the autopsy as the ‘‘gold standard’’ for the diagnosis of definitive AD in living patients (Blennow et al., 2010; Shaw et al., 2011).”
BackgroundSelf-citationThe Alzheimer's Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.008 · Cited by 1,525
Self-citationNeuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
Neuropathology of Cognitively Normal Elderly
Knopman, D. S., Parisi, J. E., Salviati, A., Floriach-Robert, M., Boeve, B. F., Ivnik, R. J., Smith, G. E., Dickson, D. W., Johnson, K. A., Petersen, L. E., et al. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.11.1087 · Cited by 674
Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden
Hedden, T., Van Dijk, K. R. A., Becker, J. A., Mehta, A., Sperling, R. A., Johnson, K. A., & Buckner, R. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3189-09.2009 · Cited by 598
Annual Incidence of Alzheimer Disease in the United States Projected to the Years 2000 Through 2050
Hebert, L. E., Beckett, L. A., Scherr, P. A., & Evans, D. A. (2001) · Alzheimer Disease and Associated Disorders · doi:10.1097/00002093-200110000-00002 · Cited by 467 · cited 1×
“These biomarker changes are not only observed in presymptomatic individuals harboring increased brain amyloid burden (Hedden et al., 2009), but also in genetic risk carriers of younger age (20–35 years), which are presumably several decades away prior to the onset of possible clinical symptoms…”
Background
Cited by
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716
Self-citationClinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.02.004 · Cited by 455
Self-citationLymphatic drainage system of the brain: A novel target for intervention of neurological diseases
Sun, B.-L., Wang, L.-H., Yang, T., Sun, J.-Y., Mao, L.-L., Yang, M.-F., Yuan, H., Colvin, R. A., & Yang, X.-Y. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.08.007 · Cited by 255
Biomarkers in Sporadic and Familial Alzheimer’s Disease
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106
Self-citationTanaka, M., Battaglia, S., & Liloia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13051045 · Cited by 24
Metadata
- Authors
- Trojanowski, J. Q., & Hampel, H.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 95
- Issue
- 4
- Pages
- 491-495
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W2133868311
- Cited by
- 54
- References
- 11
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention. https://app.cochat.ai/papers/10.1016/j.pneurobio.2011.07.004
- The paper
- Trojanowski, J. Q., & Hampel, H. (2011). Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2011.07.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.